Pharmaceutical Index
portes grátis
Pharmaceutical Index
2013 Worldwide NCEs
Pharmacodia (Beijing) Co., Ltd.
Taylor & Francis Ltd
10/2024
546
Mole
9781032918846
Pré-lançamento - envio 15 a 20 dias após a sua edição
Descrição não disponível.
Executive Summary
Chapter 1: Acotiamide Hydrochloride Hydrate
Chapter 2: Afatinib Dimaleate
Chapter 3: Canagliflozin Hemihydrate
Chapter 4: Cetilistat
Chapter 5: Cobicistat
Chapter 6: Dabrafenib Mesylate.
Chapter 7: Dimethyl Fumarate
Chapter 8: Dolutegravir Sodium
Chapter 9: Efinaconazole
Chapter 10: Elvitegravir
Chapter 11: Glycerol Phenylbutyrate
Chapter 12: Ibrutinib
Chapter 13: Istradefylline
Chapter 14: Levomilnacipran Hydrochloride
Chapter 15: Macitentan
Chapter 16: Olodaterol Hydrochloride
Chapter 17: Ospemifene
Chapter 18: Pomalidomide
Chapter 19: Riociguat
Chapter 20: Simeprevir Sodium
Chapter 21: Sofosbuvir
Chapter 22: Topiroxostat
Chapter 23: Trametinib Dimethyl Sulfoxide
Chapter 24: Vortioxetine Hydrobromide
Appendix I. Abbreviation
Appendix II. Worldwide Approved NCEs (2001-2014)
Chapter 1: Acotiamide Hydrochloride Hydrate
Chapter 2: Afatinib Dimaleate
Chapter 3: Canagliflozin Hemihydrate
Chapter 4: Cetilistat
Chapter 5: Cobicistat
Chapter 6: Dabrafenib Mesylate.
Chapter 7: Dimethyl Fumarate
Chapter 8: Dolutegravir Sodium
Chapter 9: Efinaconazole
Chapter 10: Elvitegravir
Chapter 11: Glycerol Phenylbutyrate
Chapter 12: Ibrutinib
Chapter 13: Istradefylline
Chapter 14: Levomilnacipran Hydrochloride
Chapter 15: Macitentan
Chapter 16: Olodaterol Hydrochloride
Chapter 17: Ospemifene
Chapter 18: Pomalidomide
Chapter 19: Riociguat
Chapter 20: Simeprevir Sodium
Chapter 21: Sofosbuvir
Chapter 22: Topiroxostat
Chapter 23: Trametinib Dimethyl Sulfoxide
Chapter 24: Vortioxetine Hydrobromide
Appendix I. Abbreviation
Appendix II. Worldwide Approved NCEs (2001-2014)
Este título pertence ao(s) assunto(s) indicados(s). Para ver outros títulos clique no assunto desejado.
NCEs - New Chemical Entities;Good pharmacological activity (potency and selectivity);ADME (absorption, distribution, metabolism, excretion);Chemical synthetic routes;In vitro / in vivo pharmacology;Professor Dr. K. Barry Sharpless
Executive Summary
Chapter 1: Acotiamide Hydrochloride Hydrate
Chapter 2: Afatinib Dimaleate
Chapter 3: Canagliflozin Hemihydrate
Chapter 4: Cetilistat
Chapter 5: Cobicistat
Chapter 6: Dabrafenib Mesylate.
Chapter 7: Dimethyl Fumarate
Chapter 8: Dolutegravir Sodium
Chapter 9: Efinaconazole
Chapter 10: Elvitegravir
Chapter 11: Glycerol Phenylbutyrate
Chapter 12: Ibrutinib
Chapter 13: Istradefylline
Chapter 14: Levomilnacipran Hydrochloride
Chapter 15: Macitentan
Chapter 16: Olodaterol Hydrochloride
Chapter 17: Ospemifene
Chapter 18: Pomalidomide
Chapter 19: Riociguat
Chapter 20: Simeprevir Sodium
Chapter 21: Sofosbuvir
Chapter 22: Topiroxostat
Chapter 23: Trametinib Dimethyl Sulfoxide
Chapter 24: Vortioxetine Hydrobromide
Appendix I. Abbreviation
Appendix II. Worldwide Approved NCEs (2001-2014)
Chapter 1: Acotiamide Hydrochloride Hydrate
Chapter 2: Afatinib Dimaleate
Chapter 3: Canagliflozin Hemihydrate
Chapter 4: Cetilistat
Chapter 5: Cobicistat
Chapter 6: Dabrafenib Mesylate.
Chapter 7: Dimethyl Fumarate
Chapter 8: Dolutegravir Sodium
Chapter 9: Efinaconazole
Chapter 10: Elvitegravir
Chapter 11: Glycerol Phenylbutyrate
Chapter 12: Ibrutinib
Chapter 13: Istradefylline
Chapter 14: Levomilnacipran Hydrochloride
Chapter 15: Macitentan
Chapter 16: Olodaterol Hydrochloride
Chapter 17: Ospemifene
Chapter 18: Pomalidomide
Chapter 19: Riociguat
Chapter 20: Simeprevir Sodium
Chapter 21: Sofosbuvir
Chapter 22: Topiroxostat
Chapter 23: Trametinib Dimethyl Sulfoxide
Chapter 24: Vortioxetine Hydrobromide
Appendix I. Abbreviation
Appendix II. Worldwide Approved NCEs (2001-2014)
Este título pertence ao(s) assunto(s) indicados(s). Para ver outros títulos clique no assunto desejado.